Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: July 6, 2004
Last updated: October 5, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2005
  Primary Completion Date: July 2005 (Final data collection date for primary outcome measure)